





[10] New and improved neuroactive steroids are needed that act as modulating agents for brain excitability, as well as agents for the prevention and treatment of CNS-related diseases. The compounds, compositions, and methods described herein are directed toward this end.




Summary ~~of the Invention~~




[10a] In a first aspect of the present disclosure, there is provided a compound selected from

Compound No.	Structure
19	
24	
28	
54	


Compound No.	Structure
79	
206	

[10b] In another aspect of the present disclosure, there is provided a pharmaceutically acceptable salt of a compound selected from

Compound No.	Structure
19	
24	
28	


Compound No.	Structure
54	
79	
206	

[10c] In yet another aspect of the present disclosure, there is provided a compound of the formula




.

[10d] In a further aspect of the present disclosure, there is provided a pharmaceutically acceptable salt of a compound of the formula




.

[10e] In another aspect of the present disclosure, there is provided a compound of the formula




.

[10f] In yet another aspect of the present disclosure, there is provided a pharmaceutically acceptable salt of a compound of the formula




.

[10g] In a further aspect of the present disclosure, there is provided a compound of the formula




.

[10h] In another aspect of the present disclosure, there is provided a pharmaceutically acceptable salt of a compound of the formula




.

[10i] In yet another aspect of the present disclosure, there is provided a compound of the formula




.

[10j] In a further aspect of the present disclosure, there is provided a pharmaceutically acceptable salt of a compound of the formula




.

[10k] In another aspect of the present disclosure, there is provided a compound of the formula




.

[10l] In yet another aspect of the present disclosure, there is provided a pharmaceutically acceptable salt of a compound of the formula




.

[10m] In a further aspect of the present disclosure, there is provided a compound of the formula





.





[10n] In another aspect of the present disclosure, there is provided a pharmaceutically acceptable salt of a compound of the formula



.


[10o] In yet another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound selected from






Compound No.	**Structure**
19	
24	

Compound No.	Structure
28	
54	
79	
206	

and a pharmaceutically acceptable excipient.

[10p] In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound selected from

Compound No.	Structure
19	

Compound No.	Structure
24	
28	
54	
79	
206	

and a pharmaceutically acceptable excipient.




[10q] In another aspect of the present disclosure, there is provided the compound, the pharmaceutically acceptable salt, or the pharmaceutical composition as disclosed herein, for use in inducing sedation and/or anesthesia in a subject.




[10r] In yet another aspect of the present disclosure, there is provided the compound, the pharmaceutically acceptable salt, or the pharmaceutical composition as disclosed herein, for use in tremor in a subject.

[10s] In a further aspect of the present disclosure, there is provided the compound, the pharmaceutically acceptable salt, or the pharmaceutical composition as disclosed herein, for use in treating seizure in a subject.

[10t] In another aspect of the present disclosure, there is provided the compound, the pharmaceutically acceptable salt, or the pharmaceutical composition as disclosed herein, for use in treating epilepsy or status epilepticus in a subject.


[10u] In yet another aspect of the present disclosure, there is provided a use of a compound selected from






Compound No.	**Structure**
19	
24	
28	

Compound No.	Structure
54	
79	
206	

or pharmaceutically acceptable salt thereof in the manufacture of a medicament for inducing sedation and/or anesthesia in a subject in need thereof.






[10v] In a further aspect of the present disclosure, there is provided a use of a compound selected from


Compound No.	Structure
19	

Compound No.	Structure
24	
28	
54	
79	
206	

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating tremor in a subject in need thereof.




[10w] In another aspect of the present disclosure, there is provided a use of a compound selected from




Compound No.	Structure
19	
24	
28	
54	
79	

Compound No.	Structure
206	

or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating seizure in a subject in need thereof.


[10x] In yet another aspect of the present disclosure, there is provided a use of a compound selected from






Compound No.	Structure
19	
24	
28	

Compound No.	Structure
54	
79	
206	

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating epilepsy or status epilepticus in a subject in need thereof.






[10y] In a further aspect of the present disclosure, there is provided a use of a compound selected from


Compound No.	Structure
19	

Compound No.	Structure
24	
28	
54	
79	
206	

in the manufacture of a medicament for treating a CNS-related disorder related to GABA function in a subject in need thereof.




[10z] In another aspect of the present disclosure, there is provided a use of a compound selected from




Compound No.	Structure
19	
24	
28	
54	
79	

Compound No.	Structure
206	

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an eating disorder in a subject in need thereof, wherein the eating disorder is selected from anorexia nervosa, bulimia nervosa, binge-eating disorder, and cachexia.

[10aa] In yet another aspect of the present disclosure, there is provided a use of a compound selected from


Compound No.	Structure
19	
24	
28	

Compound No.	Structure
54	
79	
206	

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Angelman's syndrome in a subject in need thereof.

[11] Provided herein are C21-substituted neuroactive steroids designed, for example, to act as GABA modulators. In certain ~~embodiments~~examples, such compounds are envisioned to be useful as therapeutic agents for the inducement of anesthesia and/or sedation in a subject. In some ~~embodiment~~examples, such compounds are envisioned to be useful as therapeutic agents for treating a CNS-related disorder (*e.g.*, sleep disorder, a mood disorder such as depression, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus) in a subject in need (*e.g.*, a subject with Rett syndrome, Fragile X syndrome, or Angelman syndrome).

In one example~~aspect~~, provided is a compound of Formula (**I**):



(**I**)

or a pharmaceutically acceptable salt thereof; wherein: ring A is substituted or unsubstituted carbocyclyl, heterocyclyl, aryl, or heteroaryl; R^1 is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, or substituted or unsubstituted C_{3-6} carbocylyl; R^2 is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, or $–OR^{A2}$, wherein R^{A2} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted


C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl; R^{3a} is hydrogen or $–OR^{A3}$, wherein R^{A3} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group; R^{4a} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or $–OR^{A4}$, wherein R^{A4} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, and R^{4b} is hydrogen or substituted or unsubstituted C_{1-6} alkyl; R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring). R^{7a} is hydrogen or halogen; R^{7b} is hydrogen; R^5 is absent or hydrogen; and ------ represents a single or double bond, wherein when one of ------ is a double bond, the other ------ is a single bond; and when one of the ------ is a double bond, R^5 is absent.

In an ~~embodiment~~example, A is Ring A is substituted or unsubstituted nitrogen containing heterocyclyl, or nitrogen containing heteroaryl. In an ~~embodiment~~example, A is attached through a nitrogen atom. In an ~~embodiment~~example, A is monocyclic heteroaryl or heterocylcyl, for example, a substituted monocyclic heteroaryl. In an ~~embodiment~~example, A is bicyclic heteroaryl, for example, a substituted bicyclic heteroaryl. Exemplary substituents are described herein.


In an ~~embodiment~~example, ring A is substituted carbocyclyl, heterocyclyl, aryl, or heteroaryl, for example, a substituted heterocyclyl or heteroaryl. In some ~~embodiment~~examples, the heterocyclyl or heteroaryl is attached through a nitrogen atom. In an ~~embodiment~~example, A is a substituted heterocyclyl linked through a nitrogen atom. In an ~~embodiment~~example, A is an unsubstituted heterocyclyl linked through a nitrogen atom. In an ~~embodiment~~example, A is a substituted heteroaryl linked through a nitrogen atom. In an ~~embodiment~~example, A is an unsubstituted heteroaryl linked through a nitrogen atom.

In an ~~embodiment~~example, A is substituted or unsubstituted imidiaole or benzimidazole (e.g., a substituted imidazole or benzimidazole). In some ~~embodiment~~examples the imidazole or benzimidazole is attached through a nitrogen atom.


In an ~~embodiment~~example, A is substituted or unsubstituted and is selected from:



In an ~~embodiment~~example, A is substituted or unsubstituted and is selected from:



In an ~~embodiment~~example A is substituted or unsubstituted and is selected from:



In an ~~embodiment~~example, R^1 is hydrogen, methyl, ethyl, or propyl (e.g., methyl). In an ~~embodiment~~example, R^1 is unsubstituted C_{1-3} alkyl. In an ~~embodiment~~example, R^1 is substituted C_{1-6} alkyl (e.g., haloalkyl or alkoxyalkyl such as methoxymethyl).


[12] In an ~~embodiment~~example, at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen. For example, in an ~~embodiment~~example, at least 2 of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.

In an ~~embodiment~~example, R^2 is substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, or $–OR^{A2}$, wherein R^{A2} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl. In an ~~embodiment~~example, R^2 is $–OR^{A2}$, wherein R^{A2} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, for example, hydroxyl or alkoxy.

In an ~~embodiment~~example, R^{3a} is $–OR^{A3}$, wherein R^{A3} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group. In an ~~embodiment~~example, R^{3a} is $–OR^{A3}$, wherein R^{A3} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, for example, hydroxyl or alkoxy

In an ~~embodiment~~example, R^{4a} is substituted or unsubstituted C_{1-6} alkyl, or $–OR^{A4}$, wherein R^{A4} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, and R^{4b} is hydrogen or substituted or unsubstituted C_{1-6} alkyl; or R^{4a} and R^{4b} are joined to form an oxo (=O) group.


In an ~~embodiment~~example, the compound is of the Formula (**I-a**):



(**I-a**)


wherein: R^6 is substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, C_{1-6} haloalkyl, halogen, cyano,–OR^{A6}, -C(=O)OR^{A6}, -SR^{B6}, -S(=O)R^{B6}, or S(=O)$_2R^{B6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, or C_{1-6} haloalkyl, and R^{B6} is substituted or unsubstituted C_{1-6} alkyl or substituted or unsubstituted C_{3-6} carbocylyl; and n is 0, 1, 2, or 3.

In an ~~embodiment~~example, the compound is of the Formula (**I-b**):




(**I-b**).

In an ~~embodiment~~example, the compound is of the Formula (**I-c1**) or (**I-c2**):




(**I-c1**)



(**I-c2**).

In an ~~emdodiment~~example, the compound is of the Formula (**I-c1**):



(**I-c1**)

or a pharmaceutically acceptable salt thereof; wherein: Ring A is substituted or unsubstituted carbocyclyl, heterocyclyl, aryl, or heteroaryl; R^1 is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, or substituted or unsubstituted C_{3-6} carbocylyl; R^2 is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, or $–OR^{A2}$, wherein R^{A2} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl; R^{3a} is hydrogen or $–OR^{A3}$, wherein R^{A3} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group; R^{4a} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, or $–OR^{A4}$, wherein R^{A4} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl,

and R^{4b} is hydrogen or substituted or unsubstituted C_{1-6} alkyl; R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring); R^6 is substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, C_{1-6} haloalkyl, halogen, cyano,–OR^{A6}, -C(=O)OR^{A6}, -SR^{B6}, -S(=O)R^{B6}, or $S(=O)_2R^{B6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, or C_{1-6} haloalkyl, and R^{B6} is substituted or unsubstituted C_{1-6} alkyl or substituted or unsubstituted C_{3-6} carbocylyl; and n is 0, 1, 2, or 3.

In an ~~embodiment~~example, A is a carbon bound (e.g., A linked through a carbon atom) substituted or unsubstituted 5 or 6-membered heteroaryl, or 6-membered aryl.

In an ~~embodiment~~example, A is Ring A is substituted or unsubstituted nitrogen containing heterocyclyl, or nitrogen containing heteroaryl. In an ~~embodiment~~example, A is attached through a nitrogen. In an ~~embodiment~~example, A is monocyclic heteroaryl or heterocylcyl, for example, a substituted monocyclic heteroaryl. In an ~~embodiment~~example, A is bicyclic heteroaryl, for example, a substituted bicyclic heteroaryl. Exemplary substituents are described herein.

[13] In an ~~embodiment~~example, R^1 is hydrogen. In an ~~embodiment~~example, R^1 is substituted or unsubstituted C_{1-6} alkyl, for example, methyl.

[14] In an ~~embodiment~~example, at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen. For example, in an ~~embodiment~~example, at least 2 of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.


In an ~~embodiment~~example, R^2 is substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, or –OR^{A2}, wherein R^{A2} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl. In an ~~embodiment~~example, R^2 is –OR^{A2}, wherein R^{A2} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, for example, hydroxyl or alkoxy.

In an ~~embodiment~~example, R^{3a} is –OR^{A3}, wherein R^{A3} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or

substituted or unsubstituted C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group. In an ~~embodiment~~example, R^{3a} is $–OR^{A3}$, wherein R^{A3} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, for example, hydroxyl or alkoxy

In an ~~embodiment~~example, R^{4a} is substituted or unsubstituted C_{1-6} alkyl, or $–OR^{A4}$, wherein R^{A4} is hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocylyl, and R^{4b} is hydrogen or substituted or unsubstituted C_{1-6} alkyl; or R^{4a} and R^{4b} are joined to form an oxo (=O) group.


In an ~~embodiment~~example, the compound is of the Formula (**II**):




(**II**)

wherein: Ring E is substituted or unsubstituted heterocyclyl or heteroaryl.

In an ~~embodiment~~example, the compound is of the Formula (**II-a1**) or (**II-a2**):



(**II-a1**)




(**II-a2**).


In an ~~embodiment~~example, E is a ring comprising at least one nitrogen atom.

In an ~~embodiment~~example, A is a ring comprising at least one nitrogen atom.


In an ~~embodiment~~example, E is selected from:



In an ~~embodiment~~example, E is selected from:



In an ~~embodiment~~example, A is:



In an ~~embodiment~~example, E is a ring comprising at least two nitrogen atoms. In an ~~embodiment~~example, E is a ring comprising at least two nitrogen atoms and R^1 is substituted or unsubstituted C_{2-6} alkyl. In an ~~embodiment~~example, E is a ring comprising at least two nitrogen atoms and at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.

In an ~~embodiment~~example, E is a ring comprising at least three nitrogen atoms. In an ~~embodiment~~example, E is a ring comprising four nitrogen atoms.

In an ~~embodiment~~example, R^1 is substituted or unsubstituted C_{2-6} alkyl.

In an ~~embodiment~~example, at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.

In an ~~embodiment~~example, E is a ring comprising 2, 3 or 4 nitrogen atoms.

In an ~~embodiment~~example, E is a ring selected from pyrazole, triazole, tetrazole, indazole, benzotriazole, triazolopyridine, triazolopyrazine, pyrazolopyrazine.

In an ~~embodiment~~example, A is a 6-membered heterocyclyl ring (e.g., a 6-membered heterocyclyl ring comprising at least two heteroatoms).

In an ~~embodiment~~example, A is a 5-6-membered heterocyclyl ring, and n is 1 or 2.

In an ~~embodiment~~example, E is morpholine and n is 1 or 2.

In an ~~embodiment~~example, R^1 is hydrogen or unsubstituted C_{1-6} alkyl. In an ~~embodiment~~example, R^1 is or methyl. In an ~~embodiment~~example, R^1 is substituted or unsubstituted C_{2-6} alkyl.

In an ~~embodiment~~example, R^2 is hydrogen, $–OR^{A2}$, wherein R^{A2} is hydrogen, or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl).

In an ~~embodiment~~example, R^{3a} is $–OR^{A3}$, wherein R^{A3} is hydrogen, or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).

In an ~~embodiment~~example, R^{3a} and R^{3b} are joined to form an oxo (=O) group.

In an ~~embodiment~~example, R^{4a} is hydrogen, or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).

In an ~~embodiment~~example, R^{4b} is hydrogen, or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).

In an ~~embodiment~~example, R^{4a} is hydrogen, and R^{4b} is substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).

In an ~~embodiment~~example, R^5 is hydrogen.

In an ~~embodiment~~example, n is 0.

In an ~~embodiment~~example, n is 1 and R^6 is substituted or unsubstituted C_{1-6} alkyl, C_{1-6} haloalkyl, halogen (e.g., -F, -Br, -Cl), cyano, $–OR^{A6}$, $-C(=O)OR^{A6}$, $-SR^{B6}$, $-S(=O)R^{B6}$, or $S(=O)_2R^{B6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl), C_{1-6} haloalkyl (e.g., $-CF_3$), and R^{B6} is substituted or unsubstituted C_{1-6} alkyl.

In an ~~embodiment~~example, n is 1 and R^6 is halogen (e.g., -F, -Br, -Cl) or cyano. In an ~~embodiment~~example, n is 1 and R^6 is substituted or unsubstituted C_{1-6} alkyl (e.g., methyl). In an ~~embodiment~~example, n is 1 and R^6 is C_{1-6} haloalkyl, $–OR^{A6}$, or $–C(=O)OR^{A6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl), C_{1-6} haloalkyl (e.g., $-CF_3$). In an ~~embodiment~~example, n is 1 and R^6 is SR^{B6}, $-S(=O)R^{B6}$, or $S(=O)_2R^{B6}$, wherein R^{B6} is substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).

In an ~~embodiment~~example, n is 2 and R^6 is independently selected from substituted or unsubstituted C_{1-6} alkyl, C_{1-6} haloalkyl, halogen (e.g., -F, -Br, -Cl), cyano,$–OR^{A6}$, $-C(=O)OR^{A6}$, -

SR^{B6}, $-S(=O)R^{B6}$, or $S(=O)_2R^{B6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl), C_{1-6} haloalkyl (e.g., $-CF_3$), and R^{B6} is substituted or unsubstituted C_{1-6} alkyl.








In an ~~embodiment~~example, n is 2 and R^6 is independently selected from halogen (e.g., -F, -Br, -Cl). In an ~~embodiment~~example, n is 2 and one of R^6 is fluorine.


In an ~~embodiment~~example, n is 0 and R^1 is substituted or unsubstituted C_{2-6} alkyl.


In an ~~embodiment~~example, R^1 is substituted or unsubstituted C_{1-6} alkyl and at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.


In an ~~embodiment~~example, the compound is of the Formula (**II-a1**) and E is a heteroaryl ring comprising at least 3 nitrogen atoms.


In an ~~embodiment~~example, the compound is:


,

,

,

,

,

,

,



,


,


or


.

In one ~~aspect~~example, provided is a pharmaceutical composition comprising a compound of the Formula (**I**) and a pharmaceutically acceptable excipient.

In one ~~aspect~~example, provided is a method of inducing sedation and/or anesthesia in a subject, comprising administering to the subject an effective amount of a compound of the Formula (**I**), or a pharmaceutically acceptable salt thereof.

In one example~~aspect~~, provided is a method of administering an effective amount of a compound, a pharmaceutically acceptable salt thereof, or pharmaceutical composition of a compound of Formula (**I**), to a subject in need thereof, wherein the subject experiences sedation and/or anesthesia within two hours of administration.

In an example~~embodiment~~, the subject experiences sedation and/or anesthesia within one hour of administration.

In an example~~embodiment~~, the subject experiences sedation and/or anesthesia instantaneously.

In an example~~embodiment~~, the compound is administered by intravenous administration.

In an example~~embodiment~~, the compound is administered chronically.

In an example~~embodiment~~, the subject is a mammal. In an ~~embodiment~~example, the subject is a human.

In an example~~embodiment~~, the compound is administered in combination with another therapeutic agent.

In one exampleaspect, provided is a method for treating seizure in a subject, comprising administering to the subject an effective amount of a compound of the Formula (**I**) or a pharmaceutically acceptable salt thereof.

In one exampleaspect, provided is a method for treating epilepsy or status or status epilepticus in a subject, the method comprising administering to the subject an effective amount of a compound of the Formula (**I**) or a pharmaceutically acceptable salt thereof. In an embodimentexample, the status epilepticus is convulsive status epilepticus (*e.g.*, early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus) or non-convulsive status epilepticus, (*e.g.*, generalized status epilepticus, complex partial status epilepticus).

In one exampleaspect, provided is a method for treating disorders related to GABA function in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound, a pharmaceutically acceptable salt thereof, or pharmaceutical composition of one of a compound of the Formula (**I**).

In one exampleaspect, provided is a method for treating a CNS-related disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the Formula (**I**) or a pharmaceutically acceptable salt thereof.

In an exampleembodiment, the CNS-related disorder is a sleep disorder, a mood disorder such as depression, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.

In an exampleembodiment, the subject is a subject with Rett syndrome, Fragile X syndrome, or Angelman syndrome. In an embodimentexample, the CNS–related disorder is a sleep disorder, an eating disorder, a mood disorder such as depression, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus. In an embodimentexample, the CNS-related disorder is depression (e.g., post-partum depression). In an embodimentexample, the CNS-related disorder is

tremor (e.g., essential tremor). In an ~~embodiment~~example, the CNS-related disorder is an eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, cachexia).

In an example~~embodiment~~, the compound is administered orally. In an ~~embodiment~~example, the compound is administered intramuscularly.

In one example~~aspect~~, provided is a kit comprising a solid composition comprising a compound of Formula (**I**) and a sterile diluent.

[15] The present ~~invention~~disclosure also provides pharmaceutical compositions comprising a compound of the present ~~invention~~disclosure and methods of use and treatment, *e.g.*, such as for inducing sedation and/or anesthesia, for treating a CNS-related disorder.

[16] Steroids of Formula (**I**), sub-genera thereof, and pharmaceutically acceptable salts thereof are collectively referred to herein as "compounds of the present ~~invention~~disclosure."

[17] In another example~~aspect~~, provided is a pharmaceutical composition comprising a compound of the present ~~invention~~disclosure and a pharmaceutically acceptable excipient. In certain ~~embodiment~~examples, the compound of the present ~~invention~~disclosure is provided in an effective amount in the pharmaceutical composition. In certain ~~embodiment~~examples, the compound of the present ~~invention~~disclosure is provided in a therapeutically effective amount. In certain ~~embodiment~~examples, the compound of the present ~~invention~~disclosure is provided in a prophylactically effective amount.

[18] Compounds of the present ~~invention~~disclosure as described herein, act, in certain ~~embodiment~~examples, as GABA modulators, *e.g.*, effecting the $GABA_A$ receptor in either a positive or negative manner. As modulators of the excitability of the central nervous system (CNS), as mediated by their ability to modulate $GABA_A$ receptor, such compounds are expected to have CNS-activity.

[19] Thus, in another example~~aspect~~, provided are methods of treating a CNS–related disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the present ~~invention~~disclosure. In certain ~~embodiment~~examples, the CNS–related disorder is selected from the group consisting of a sleep disorder, a mood disordersuch as depression, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, and tinnitus. In certain ~~embodiment~~examples, the compound is administered orally, subcutaneously, intravenously, or

intramuscularly. In certain ~~embodiment~~examples, the compound is administered chronically. In certain ~~embodiment~~examples, the compound is administered continuously, *e.g.*, by continuous intravenous infusion.

[20] Other objects and advantages will become apparent to those skilled in the art from a consideration of the ensuing **Detailed Description**, **Examples**, and **Claims**.

Definitions

Chemical definitions


[21] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, *Handbook of Chemistry and Physics*, 75th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, *Organic Chemistry*, University Science Books, Sausalito, 1999; Smith and March, *March's Advanced Organic Chemistry*, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, *Comprehensive Organic Transformations*, VCH Publishers, Inc., New York, 1989; and Carruthers, *Some Modern Methods of Organic Synthesis*, 3rd Edition, Cambridge University Press, Cambridge, 1987.

[22] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, *e.g.*, enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC)), supercritical fluid chromatography (SFC), and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques *et al.*, *Enantiomers, Racemates and Resolutions* (Wiley Interscience, New York, 1981); Wilen *et al.*, *Tetrahedron* 33:2725 (1977); Eliel, *Stereochemistry of Carbon Compounds* (McGraw–Hill, NY, 1962); and Wilen, *Tables of Resolving Agents and Optical*

Claims

What is claimed is:

1. A compound of the Formula (I):



(I)

or a pharmaceutically acceptable salt thereof;

wherein:

Ring A is carbocyclyl, heterocyclyl, aryl, or heteroaryl;

R^1 is hydrogen, C_{1-5}haloalkyl (e.g., C_{1-3}haloalkyl), C_{1-5}alkyl (e.g., C_{1-3}alkyl), C_{2-6} alkenyl, or C_{3-6}carbocylyl;

each of R^{2a} and R^{2b} is independently hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6} carbocylyl, or $-OR^{A2}$, wherein R^{A2} is hydrogen or C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, or C_{3-6} carbocylyl;

R^{3a} is hydrogen or $-OR^{A3}$, wherein R^{A3} is hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, or C_{3-6}carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group;


R^{4a} is hydrogen, C_{1-6}alkyl, or $-OR^{A4}$, wherein R^{A4} is hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, or C_{3-6}carbocylyl, and R^{4b} is hydrogen or C_{1-6}alkyl; or R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring);

R^5 is absent or hydrogen;

each of R^{7a} and R^{7b} is independently hydrogen or halogen;

------ represents a single or double bond, wherein when one of ------ is a double bond, the other ------ is a single bond; and when one of the ------ is a double bond, R^5 is absent.

2. The compound of claim 1, wherein the compound is a compound of Formula (**I-a**):



(**I-a**)

or a pharmaceutically acceptable salt thereof;

wherein:


R^6 is C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}carbocylyl, C_{1-6}haloalkyl, halogen, cyano, nitro, OR^{A6}, $C(=O)R^{A6}$, $C(=O)OR^{A6}$, SR^{B6}, $S(=O)R^{B6}$, $S(=O)_2R^{B6}$, $N(R^{C6})(R^{D6})$, $C(=O)N(R^{C6})(R^{D6})$, $N(R^{C6})C(=O)R^{A6}$; and


n is 0, 1, 2, or 3;


wherein R^{A6} is hydrogen or C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}carbocylyl, or C_{1-6}haloalkyl; R^{B6} is C_{1-6}alkyl or C_{3-6}carbocylyl; and each of R^{C6} and R^{D6} is independently hydrogen, C_{1-6}alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl, or R^{C6} and R^{D6} together with the nitrogen atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring)).


3. The compound of any one of the preceding claims, wherein A is a carbon bound (e.g., A linked through a carbon atom) 5 or 6-membered heteroaryl, or 6-membered aryl.


4. The compound of claim 3, wherein A is:



, 

, 

, 

, or 

,

wherein:

X is –O–, –S–, or –N(R^N)–, wherein R^N is independently hydrogen, C_{1-6}alkyl, –C(=O)R^{GA}, –C(=O)OR^{GA}, –C(=O)N(R^{GA})$_2$, –S(=O)$_2$$R^{GA}$, –S(=O)$_2OR^{GA}$, –S(=O)$_2$N($R^{GA}$)$_2$, or a nitrogen protecting group;

each instance of R^{6a}, R^{6b}, R^{6c}, R^{6d}, and R^{6e} is, independently, hydrogen, halogen, –NO_2, –CN, –OR^{GA}, –N(R^{GA})$_2$, –C(=O)R^{GA}, –C(=O)OR^{GA}, –OC(=O)R^{GA}, –OC(=O)OR^{GA}, –C(=O)N(R^{GA})$_2$, –N(R^{GA})C(=O)R^{GA}, –OC(=O)N(R^{GA})$_2$, –N(R^{GA})C(=O)OR^{GA}, –N(R^{GA})C(=O)N(R^{GA})$_2$, –S(=O)$_2$$R^{GA}$, –S(=O)$_2OR^{GA}$, –OS(=O)$_2$$R^{GA}$, –S(=O)$_2$N($R^{GA}$)$_2$, –N($R^{GA}$)S(=O)$_2$$R^{GA}$, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6}carbocylyl, or 3- to 6- membered heterocylyl; or two of R^{6a}, R^{6b}, R^{6c}, R^{6d}, and R^{6e} are taken with the atoms to which they are attached to form a heterocyclyl, aryl, or heteroaryl ring; and

each instance of R^{GA} is independently hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-6} carbocylyl, 3- to 6- membered heterocylyl, aryl, heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two R^{GA} groups are taken with the intervening atoms to form a heterocylyl or heteroaryl ring.

5. The compound of claim 4, wherein at least one of R^{6a}, R^{6b}, R^{6c}, R^{6d}, and R^{6e} is hydrogen.


6. The compound of claim 4, wherein at least one of R^{6a}, R^{6b}, R^{6c}, R^{6d}, and R^{6e} is C_{1-2}alkyl, –$CO_2$$R^{GA}$, –C(=O)$R^{GA}$, –CN, –$NO_2$, or halogen, wherein R^{GA} is C_{1-2}alkyl.

7. The compound of claim 5, wherein at least one of R^{6a}, R^{6b}, R^{6c}, R^{6d}, and R^{6e} is –CH_3.

8. The compound of claim 4, wherein R^{6a}, R^{6b}, R^{6c}, R^{6d}, and R^{6e} are hydrogen.

9. The compound of claim 4, wherein A is a ring comprising at least one nitrogen atom.

~~10. The compound of any one of the preceding claims, wherein the compound is of the Formula (II-b):~~




~~(II-b).~~

~~wherein:~~

~~Ring E is heterocyclyl or heteroaryl.~~


~~11. The compound of claim 10, wherein E is a ring comprising at least one nitrogen atom.~~

~~12. The compound of claim 11, wherein E is selected from:~~



~~or~~ .

~~13. The compound of any one of the preceding claims, wherein A is:~~



14. The compound of any one of claims 10-12, wherein E is a ring comprising at least two nitrogen atoms.

15. The compound of claim 14, wherein E is a ring comprising at least two nitrogen atoms and at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.

16. The compound of any one of claims 10-15, wherein E is a ring comprising at least three nitrogen atoms.

17. The compound of any one of claims 10-16, wherein E is a ring comprising four nitrogen atoms.

18. The compound of claim 17, wherein at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.

19. The compound of any one of claims 10-18, wherein E is a ring comprising 2, 3 or 4 nitrogen atoms.

20. The compound of any one of claims 10-199, wherein E is a ring selected from pyrazole, triazole, tetrazole, indazole, benzotriazole, triazolopyridine, triazolopyrazine, pyrazolopyrazine, or morpholine.

21. The compound of any one of claims1-2, wherein A is a 6-membered heterocyclyl ring (e.g., a 6-membered heterocyclyl ring comprising at least two heteroatoms).

22. The compound of any one of claims 1-2, wherein A is a 5-6-membered heterocyclyl ring, and n is 1 or 2.

23. The compound of claim 10, wherein E is morpholine and n is 1 or 2.

24. The compound of any one of the preceding claims, wherein A is an aryl ring.

25. The compound of any one of the preceding claims, wherein A is phenyl and n is 1 or 2.

26. The compound of any one of the preceding claims, wherein R^1 is hydrogen, substituted C_{1-3} alkyl, or unsubstituted C_{1-3} alkyl.

27. The compound of any one of the preceding claims, wherein R^1 is hydrogen, methyl, or methoxymethyl.

28. The compound of claim 27, wherein R^1 is methyl.

29. The compound of any one of the preceding claims, wherein R^2 is hydrogen, OR^{A2}, wherein R^{A2} is hydrogen, or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl).

30. The compound of any one of the preceding claims, wherein R^{3a} is –OR^{A3}, wherein R^{A3} is hydrogen, or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).

31. The compound of claim 1, wherein R^{3a} and R^{3a} are joined to form an oxo (=O) group.

32. The compound of any one of the preceding claims, wherein R^{4a} is hydrogen, substituted C_{1-6} alkyl, or unsubstituted C_{1-6} alkyl (e.g., methyl).

33. The compound of any one of the preceding claims, wherein R^{4b} is hydrogen, or substituted C_{1-6} alkyl, or unsubstituted C_{1-6} alkyl (e.g., methyl).

34. The compound of claim 1, wherein R^{4a} is hydrogen, and R^{4b} is substituted C_{1-6} alkyl or unsubstituted C_{1-6} alkyl (e.g., methyl).

35. The compound of any one of the preceding claims, wherein each of R^{4a} and R^{4a} is independently unsubstituted C_{1-6} alkyl (e.g., methyl).

36. The compound of any one of the preceding claims, wherein each of R^{4a} and R^{4a} is independently hydrogen.

37. The compound of any one of the preceding claims, wherein R^{5} is hydrogen.

38. The compound of any one of the preceding claims, wherein n is 0.

39. The compound of any one of the preceding claims, wherein n is 1 and R^{6} is substituted or unsubstituted C_{1-6} alkyl, C_{1-6} haloalkyl, halogen (e.g., –F, –Br, –Cl), cyano, –OR^{A6}, –$C(=O)OR^{A6}$, –SR^{B6}, –$S(=O)R^{B6}$, or $S(=O)_2R^{B6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl), C_{1-6} haloalkyl (e.g., $-CF_3$), and R^{B6} is substituted or unsubstituted C_{1-6} alkyl.

~~40. The compound of any one of the preceding claims, wherein n is 1 and R^6 is halogen (e.g., -F, -Br, -Cl) or cyano.~~

~~41. The compound of any one of the preceding claims, wherein n is 1 and R^6 is substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).~~

~~42. The compound of any one of the preceding claims, wherein n is 1 and R^6 is C_{1-6} haloalkyl, $-OR^{A6}$, or $-C(=O)OR^{A6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl), C_{1-6} haloalkyl (e.g., $-CF_3$).~~

~~43. The compound of any one of the preceding claims, wherein n is 1 and R^6 is SR^{B6}, $-S(=O)R^{B6}$, or $S(=O)_2R^{B6}$, wherein R^{B6} is substituted or unsubstituted C_{1-6} alkyl (e.g., methyl).~~

~~44. The compound of any one of the preceding claims, wherein n is 2 and R^6 is i4dependently selected from substituted or unsubstituted C_{1-6} alkyl, C_{1-6} haloalkyl, halogen (e.g., -F, -Br, -Cl), cyano, $-OR^{A6}$, $-C(=O)OR^{A6}$, $-SR^{B6}$, $-S(=O)R^{B6}$, or $S(=O)_2R^{B6}$, wherein R^{A6} is hydrogen or substituted or unsubstituted C_{1-6} alkyl (e.g., methyl, ethyl), C_{1-6} haloalkyl (e.g., $-CF_3$), and R^{B6} is substituted or unsubstituted C_{1-6} alkyl.~~












~~45. The compound of any one of the preceding claims, wherein n is 2 and R^6 is independently selected from halogen (e.g., -F, -Br, -Cl).~~

~~46. The compound of any one of the preceding claims, wherein n is 2 and one of R^6 is fluorine.~~


~~47. The compound of any one of the preceding claims, wherein R^1 is unsubstituted C_{1-3} alkyl and at least one of R^2, R^{3a}, R^{4a} or R^{4b} is not hydrogen.~~


~~48. The compound of claim 10, wherein the compound is of the Formula (**II-b**) and E is a heteroaryl ring comprising at least 3 nitrogen atoms.~~


~~49. The compound of claim 1, wherein the compound is:~~















241

































































































,

,

,

,

,

,

,

,

,

,

,

,

















,



,



,



,



,



,



,












,












,













,












,












,




























































































































































































































































































































; 


;




; 


;



; 

;




or 

.

~~50. A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable excipient.~~

~~51. A method of inducing sedation and/or anesthesia in a subject, comprising administering to the subject an effective amount of a compound of the Formula (I):~~



(I)

or a pharmaceutically acceptable salt thereof;

wherein:

Ring A is carbocyclyl, heterocyclyl, aryl, or heteroaryl;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{3-6} carbocylyl;

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} carbocylyl, or $-OR^{A2}$, wherein R^{A2} is hydrogen or C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl;

R^{3a} is hydrogen or $-OR^{A3}$, wherein R^{A3} is hydrogen, C_{1-6} alkyl C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group;

R^{4a} is hydrogen, C_{1-6} alkyl, or $-OR^{A4}$, wherein R^{A4} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{4b} is hydrogen or C_{1-6} alkyl; R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring).

R^{7a} is hydrogen or halogen;

R^{7b} is hydrogen;

R^5 is absent or hydrogen; and

------ represents a single or double bond, wherein

when one of ------ is a double bond, the other ------ is a single bond; and

when one of the ------ is a double bond, R^5 is absent.

52. A method of administering an effective amount of a compound, a pharmaceutically acceptable salt thereof, or pharmaceutical composition of a compound of claim 1, to a subject in need thereof, wherein the subject experiences sedation and/or anesthesia within two hours of administration.

~~53. The method of claim 52, wherein the subject experiences sedation and/or anesthesia within one hour of administration.~~

~~54. The method of claim 52, wherein the subject experiences sedation and/or anesthesia instantaneously.~~

~~51. The method of claim 52, wherein the compound is administered by intravenous administration.~~


~~56. The method of claim 52, wherein the compound is administered chronically.~~

~~57. The method of claim 52, wherein the subject is a mammal.~~

~~58. The method of claim 57, wherein the subject is a human.~~

~~59. The method of claim 52, wherein the compound is administered in combination with another therapeutic agent.~~

~~60. A method for treating seizure in a subject, comprising administering to the subject an effective amount of a compound of the Formula (I):~~



~~(I)~~

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein:~~

Ring A is carbocyclyl, heterocyclyl, aryl, or heteroaryl;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{3-6} carbocylyl;

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} carbocylyl, or $-OR^{A2}$, wherein R^{A2} is hydrogen or C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl;

R^{3a} is hydrogen or $-OR^{A3}$, wherein R^{A3} is hydrogen, C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group;

R^{4a} is hydrogen, C_{1-6} alkyl, or $-OR^{A4}$, wherein R^{A4} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{4b} is hydrogen or C_{1-6} alkyl; R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring).

R^{7a} is hydrogen or halogen;

R^{7b} is hydrogen;


R^5 is absent or hydrogen; and

------ represents a single or double bond, wherein

when one of ------ is a double bond, the other ------ is a single bond; and

when one of the ------ is a double bond, R^5 is absent.

61. A method for treating epilepsy or status or status epilepticus in a subject, the method comprising administering to the subject an effective amount of a compound of the Formula (**I**):



(**I**)

or a pharmaceutically acceptable salt thereof;

wherein:

Ring A is carbocyclyl, heterocyclyl, aryl, or heteroaryl;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{3-6} carbocylyl;

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} carbocylyl, or $-OR^{A2}$, wherein R^{A2} is hydrogen or C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl;

R^{3a} is hydrogen or $-OR^{A3}$, wherein R^{A3} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group;

R^{4a} is hydrogen, C_{1-6} alkyl, or $-OR^{A4}$, wherein R^{A4} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{4b} is hydrogen or C_{1-6} alkyl; R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring).

R^{7a} is hydrogen or halogen;

R^{7b} is hydrogen;

R^5 is absent or hydrogen; and


------ represents a single or double bond, wherein

when one of ------ is a double bond, the other ------ is a single bond; and

when one of the ------ is a double bond, R^5 is absent.

62. The method of claim 61, wherein the status epilepticus is convulsive status epilepticus (*e.g.*, early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus) or non-convulsive status epilepticus, (*e.g.*, generalized status epilepticus, complex partial status epilepticus).

63. A method for treating disorders related to GABA function in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound, a pharmaceutically acceptable salt thereof, or pharmaceutical composition of one of a compound of Formula (**I**):



(I)

or a pharmaceutically acceptable salt thereof;

wherein:

Ring A is carbocyclyl, heterocyclyl, aryl, or heteroaryl;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{3-6} carbocylyl;

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} carbocylyl, or $-OR^{A2}$, wherein R^{A2} is hydrogen or C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl;

R^{3a} is hydrogen or $-OR^{A3}$, wherein R^{A3} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group;

R^{4a} is hydrogen, C_{1-6} alkyl, or $-OR^{A4}$, wherein R^{A4} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{4b} is hydrogen or C_{1-6} alkyl; R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring).

R^{7a} is hydrogen or halogen;

R^{7b} is hydrogen;

R^5 is absent or hydrogen; and

------ represents a single or double bond, wherein

when one of ------ is a double bond, the other ------ is a single bond; and

when one of the ------ is a double bond, R^5 is absent.

64. A method for treating a CNS-related disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any of the preceding claims, or a pharmaceutically acceptable salt thereof.

65. The method of claim 64, wherein the CNS-related disorder is a sleep disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.

66. The method of claim 64, wherein the compound is administered orally.

67. The method of claim 64, wherein the compound is administered intramuscularly.

68. The method of claim 64, wherein the subject is a subject with Rett syndrome, Fragile X syndrome, or Angelman syndrome.


69. The method of claim 64, wherein the CNS-related disorder is a sleep disorder, an eating disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.

70. The method of claim 64, wherein the CNS-related disorder is depression (e.g., post-partum depression).

71. The method of claim 64, wherein the CNS-related disorder is tremor (e.g., essential tremor).

72. The method of claim 64, wherein the CNS-related disorder is an eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, cachexia).

73. A kit comprising a solid composition comprising a compound of Formula (**I**):



(I)

or a pharmaceutically acceptable salt thereof;

wherein:

Ring A is carbocyclyl, heterocyclyl, aryl, or heteroaryl;

R^1 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, or C_{3-6} carbocylyl;

R^2 is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} carbocylyl, or $-OR^{A2}$, wherein R^{A2} is hydrogen or C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl;

R^{3a} is hydrogen or $-OR^{A3}$, wherein R^{A3} is hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group;

R^{4a} is hydrogen, C_{1-6} alkyl, or $-OR^{A4}$, wherein R^{A4} is hydrogen, C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, C_{2-6} alkynyl, or C_{3-6} carbocylyl, and R^{4b} is hydrogen or C_{1-6} alkyl; R^{4a} and R^{4b} are joined to form an oxo (=O) group; or R^{4a} and R^{4b} together with the carbon atom to which they are attached form a ring (e.g., a 3-6-membered ring (e.g., carbocycyl or heterocyclyl ring).

R^{7a} is hydrogen or halogen;

R^{7b} is hydrogen;

R^5 is absent or hydrogen; and






------ represents a single or double bond, wherein


when one of ------ is a double bond, the other ------ is a single bond; and

when one of the ------ is a double bond, R^5 is absent;




and a sterile diluent.




1. A compound selected from

Compound No.	Structure
19	
24	
28	
54	
79	


Compound No.	Structure
206	

2. A pharmaceutically acceptable salt of a compound selected from


Compound No.	Structure
19	
24	
28	

Compound No.	Structure
54	
79	
206	

3. A compound of the formula




4. A pharmaceutically acceptable salt of a compound of the formula




.

5. A compound of the formula




.

6. A pharmaceutically acceptable salt of a compound of the formula




.

7. A compound of the formula




.

8. A pharmaceutically acceptable salt of a compound of the formula




.

9. A compound of the formula




.

10. A pharmaceutically acceptable salt of a compound of the formula




.

11. A compound of the formula




.

12. A pharmaceutically acceptable salt of a compound of the formula




.

13. A compound of the formula




.






14. A pharmaceutically acceptable salt of a compound of the formula



.





15. A pharmaceutical composition comprising a compound selected from



Compound No.	**Structure**
19	

Compound No.	Structure
24	
28	
54	
79	
206	

and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound selected from

Compound No.	Structure
19	
24	
28	
54	

Compound No.	Structure
79	
206	

and a pharmaceutically acceptable excipient.

17. The compound of any one of claims 1, 3, 5, 7, 9, 11, or 13, the pharmaceutically acceptable salt of claim 2, 4, 6, 8, 10, 12, or 14, or the pharmaceutical composition of claim 15 or 16, for use in inducing sedation and/or anesthesia in a subject.

18. The compound of any one of claims 1, 3, 5, 7, 9, 11, or 13, the pharmaceutically acceptable salt of claim 2, 4, 6, 8, 10, 12, or 14, or the pharmaceutical composition of claim 15 or 16, for use in tremor in a subject.

19. The compound of any one of claims 1, 3, 5, 7, 9, 11, or 13, the pharmaceutically acceptable salt of claim 2, 4, 6, 8, 10, 12, or 14, or the pharmaceutical composition of claim 15 or 16, for use of claim 18, wherein the tremor is essential tremor.






20. The compound of any one of claims 1, 3, 5, 7, 9, 11, or 13, the pharmaceutically acceptable salt of claim 2, 4, 6, 8, 10, 12, or 14, or the pharmaceutical composition of claim 15 or 16, for use of claim 18, wherein the tremor is parkinsonian tremor.


21. The compound of any one of claims 1, 3, 5, 7, 9, 11, or 13, the pharmaceutically acceptable salt of claim 2, 4, 6, 8, 10, 12, or 14, or the pharmaceutical composition of claim 15 or 16, for use in treating seizure in a subject.

22. The compound of any one of claims 1, 3, 5, 7, 9, 11, or 13, the pharmaceutically acceptable salt of claim 2, 4, 6, 8, 10, 12, or 14, or the pharmaceutical composition of claim 15 or 16, for use in treating epilepsy or status epilepticus in a subject.

23. Use of a compound selected from




Compound No.	**Structure**




Compound No.	Structure
19	
24	
28	
54	
79	

Compound No.	Structure
206	

or pharmaceutically acceptable salt thereof in the manufacture of a medicament for inducing sedation and/or anesthesia in a subject in need thereof.

24. Use of a compound selected from

Compound No.	Structure
19	
24	
28	

Compound No.	Structure
54	
79	
206	






or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating tremor in a subject in need thereof.


25. The use of claim 24, wherein the tremor is essential tremor.

26. The use of claim 24, wherein the tremor is parkinsonian tremor.

27. Use of a compound selected from




Compound No.	Structure




Compound No.	Structure
19	
24	
28	
54	
79	

Compound No.	Structure
206	

or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating seizure in a subject in need thereof.


28. Use of a compound selected from






Compound No.	Structure
19	
24	
28	

Compound No.	Structure
54	
79	
206	

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating epilepsy or status epilepticus in a subject in need thereof.

29. Use of a compound selected from

Compound No.	Structure
19	

Compound No.	Structure
24	
28	
54	
79	
206	

in the manufacture of a medicament for treating a CNS-related disorder related to GABA function in a subject in need thereof.

30. The use of claim 29, wherein the CNS-related disorder is selected from the group consisting of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders (ASD), pain, traumatic brain injury (TBI), vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

31. The use of claim 29, wherein the CNS-related disorder is depression.

32. The use of claim 31, wherein the depression is postpartum depression.






33. The use of claim 31, wherein the depression is a major depressive disorder.


34. The use of claim 33, wherein the major depressive disorder is a severe major depressive disorder.

35. The use of claim 33, wherein the major depressive disorder is a moderate major depressive disorder.

36. Use of a compound selected from



Compound No.	**Structure**





Compound No.	Structure
19	
24	
28	
54	
79	

Compound No.	Structure
206	

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an eating disorder in a subject in need thereof, wherein the eating disorder is selected from anorexia nervosa, bulimia nervosa, binge-eating disorder, and cachexia.

37. Use of a compound selected from

Compound No.	Structure
19	
24	

Compound No.	Structure
28	
54	
79	
206	

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Angelman's syndrome in a subject in need thereof.

38. The use of any one of claims 23-38, wherein the medicament is to be administered orally or intramuscularly.

39. The use of claim 38, wherein the medicament is to be administered orally.

40. The use of claim 39, wherein the medicament is a tablet.

41. The use of claim 38, wherein the medicament is to be administered intramuscularly.

42. The use of any one of claims 23-41, wherein the medicament is to be administered chronically.

43. The use of any one of claims 23-42, wherein the subject is a human.